✦ LIBER ✦

Absence of FLT3 and JAK2 (V617F) mutations in Langerhans cell histiocytosis

✍ Scribed by Malak Abedalthagafi; Huimin Guo; Dan-Paul Hartmann; Metin Ozdemirli

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 84 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2009.03.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Absence of FTL3 mutations in patients wi

Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia

✍ Bruno C. Medeiros; Tong Zhang; Jeffrey H. Lipton; Suzanne Kamel-Reid 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

Association of essential thrombocythemia

Association of essential thrombocythemia and chronic lymphocytic leukemia: Absence of the V617F JAK2 mutation in the lymphoid compartment

✍ Laurent Henry; Serge Carillo; Eric Jourdan; Anne Arnaud; Sophie Brun; Thierry La 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB 👁 1 views

Correlations of JAK2–V617F mutation with

Correlations of JAK2–V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders

✍ Matthaios Speletas; Eirini Katodritou; Chrisoula Daiou; Eudokia Mandala; Emmanou 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 212 KB

Recently, the acquired mutation JAK2-V617F has been described in the majority of patients with myeloproliferative disorders (MPDs). In this study we evaluated its clinical and laboratory correlates in 166 patients with MPDs. The mutation was detected by allele-specific PCR in 119 patients: 81.4% (35

Use of indomethacin in Langerhans cell h

Use of indomethacin in Langerhans cell histiocytosis

✍ Munn, Stephanie E.; Olliver, Lucy; Broadbent, Valerie; Pritchard, Jon 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 2 views

Background. Because prostaglandin (PG) E2 has been identified in the bone lesions of Langerhans cell histiocytosis (LCH), we speculated that indomethacin, a potent PG inhibitor, may be useful in patients with symptomatic LCH involving the bony skeleton. Procedure. We used indomethacin to treat patie

JAK2V617F mutation can occur exclusively

JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders

✍ Barbara K. Zehentner; Michael R. Loken; Denise A. Wells 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 1 views

Simultaneous occurrence of the JAK2V617F

Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders

✍ Yeo-Kyeoung Kim; Myung-Geun Shin; Hye-Ran Kim; Deok-Hwan Yang; Sang-Hee Cho; Je- 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 284 KB